Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures

Judith LZ Weisenberg, Michael WongDepartment of Neurology, Washington University School of Medicine, St Louis, MO, USAAbstract: Epilepsy is a common disease with significant morbidity and mortality. Approximately one-third of patients with epilepsy are refractory to available seizure medications, em...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Weisenberg JLZ, Wong M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/7567d65adbf542fab236e53470f8f4bf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7567d65adbf542fab236e53470f8f4bf
record_format	dspace
spelling	oai:doaj.org-article:7567d65adbf542fab236e53470f8f4bf2021-12-02T07:56:56ZProfile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures1176-63281178-2021https://doaj.org/article/7567d65adbf542fab236e53470f8f4bf2011-07-01T00:00:00Zhttp://www.dovepress.com/profile-of-ezogabine-retigabine-and-its-potential-as-an-adjunctive-tre-a7822https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Judith LZ Weisenberg, Michael WongDepartment of Neurology, Washington University School of Medicine, St Louis, MO, USAAbstract: Epilepsy is a common disease with significant morbidity and mortality. Approximately one-third of patients with epilepsy are refractory to available seizure medications, emphasizing the need to develop better drugs with novel mechanisms of action. Ezogabine, also known as retigabine, is a new potential adjunctive treatment for adults with intractable partial seizures. Ezogabine has a unique mechanism of action consisting of activating KCNQ2/3 (Kv7) potassium channels. Ezogabine has undergone a number of Phase II and III trials demonstrating efficacy at 600,900 and 1200 mg/day in a dose-dependent fashion. The most common adverse events with ezogabine are central nervous system effects, particularly dizziness and somnolence. Urologic symptoms, particularly urinary retention, represent a rare but unique side effect of ezogabine. Ezogabine is predominantly metabolized via glucuronidation. Its half-life is 8 hours, suggesting a need for three-times-a-day administration. Ezogabine exhibits minimal interactions with other seizure medications, except possibly lamotrigine. Ezogabine has potential for clinical applications in other medical conditions beyond epilepsy, such as neuropathic pain, neuromyotonia, and bipolar disease, but these are based primarily on experimental models.Keywords: antiepileptic drug, epilepsy, ezogabineWeisenberg JLZWong MDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2011, Iss Issue 1, Pp 409-414 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Weisenberg JLZ Wong M Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures
description	Judith LZ Weisenberg, Michael WongDepartment of Neurology, Washington University School of Medicine, St Louis, MO, USAAbstract: Epilepsy is a common disease with significant morbidity and mortality. Approximately one-third of patients with epilepsy are refractory to available seizure medications, emphasizing the need to develop better drugs with novel mechanisms of action. Ezogabine, also known as retigabine, is a new potential adjunctive treatment for adults with intractable partial seizures. Ezogabine has a unique mechanism of action consisting of activating KCNQ2/3 (Kv7) potassium channels. Ezogabine has undergone a number of Phase II and III trials demonstrating efficacy at 600,900 and 1200 mg/day in a dose-dependent fashion. The most common adverse events with ezogabine are central nervous system effects, particularly dizziness and somnolence. Urologic symptoms, particularly urinary retention, represent a rare but unique side effect of ezogabine. Ezogabine is predominantly metabolized via glucuronidation. Its half-life is 8 hours, suggesting a need for three-times-a-day administration. Ezogabine exhibits minimal interactions with other seizure medications, except possibly lamotrigine. Ezogabine has potential for clinical applications in other medical conditions beyond epilepsy, such as neuropathic pain, neuromyotonia, and bipolar disease, but these are based primarily on experimental models.Keywords: antiepileptic drug, epilepsy, ezogabine
format	article
author	Weisenberg JLZ Wong M
author_facet	Weisenberg JLZ Wong M
author_sort	Weisenberg JLZ
title	Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures
title_short	Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures
title_full	Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures
title_fullStr	Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures
title_full_unstemmed	Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures
title_sort	profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/7567d65adbf542fab236e53470f8f4bf
work_keys_str_mv	AT weisenbergjlz profileofezogabineretigabineanditspotentialasanadjunctivetreatmentforpatientswithpartialonsetseizures AT wongm profileofezogabineretigabineanditspotentialasanadjunctivetreatmentforpatientswithpartialonsetseizures
_version_	1718399049446457344

Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures

Ejemplares similares